Taplin, M., Gleave, M., Shore, N. D., Lopez-Gitlitz, A., Kretschmer, A., Efstathiou, E., Damião, R., Kamoto, T., Ross, A., Briganti, A., Hadaschik, B. A., Heidenreich, A., Soto, Ã. J., Rooney, O. B., Tian, S. K., Wetherhold, L., Miladinovic, B., McCarthy, S., Evans, C. P., Kibel, A. S. (2026). Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba1